Expression and purification of monospecific and bispecific recombinant antibody fragments derived from antibodies that block the CD80/CD86-CD28 costimulatory pathway

被引:4
|
作者
Dincq, S
Bosman, F
Buyse, MA
Degrieck, R
Celis, L
de Boer, M
Van Doorsselaere, V
Sablon, E
机构
[1] Innogenet NV, Dept Microbiol, Ghent, Belgium
[2] Innogenet NV, Dept Purificat, Ghent, Belgium
[3] Tanox Pharma BV, Amsterdam, Netherlands
关键词
D O I
10.1006/prep.2001.1417
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The development of recombinant techniques for rapid cloning, expression, and characterization of cDNAs encoding antibody (Ab) subunits has revolutionized the field of antibody engineering. By fusion to heterologous protein domains, chain shuffling, or inclusion of self-assembly motifs, novel molecules such as bispecific Abs can be generated that possess the subset of functional properties designed to fit the intended application. We describe the engineering of Ab fragments produced in bacteria for blocking the CD28-CD80/CD86 costimulatory interaction in order to induce tolerance against transplanted organs. We designed single-chain Fv antibodies, monospecific and bispecific diabodies, and a bispecific tetravalent anti body (BiTAb) molecule directed against the CD80 and/or CD86 costimulatory molecules. These recombinant Ab molecules were expressed in Escherichia coli, followed by purification and evaluation for specific inter action with their respective antigen in an enzyme-linked immunosorbent assay (ELISA), A specific sandwich ELISA confirmed the bispecificity of the bispecific diabodies and the BiTAb. (C) 2001 Academic Press.
引用
收藏
页码:11 / 24
页数:14
相关论文
共 50 条
  • [31] Blockade of CD80/CD86-CD28 co-stimulation augments the inhibitory func-tion of peptide antigen-specific regulatory T cells
    Maehara, Yui
    Takeda, Kazuyoshi
    Tsuji-Yogo, Kyoko
    Morimoto, Kodai
    Harada, Masaki
    Kuriyama, Kyohei
    Hirota, Saori
    Yagita, Hideo
    Okumura, Ko
    Uchida, Koichiro
    BIOMEDICAL RESEARCH-TOKYO, 2024, 45 (03): : 115 - 123
  • [32] Evaluation of CD86/CD28 and CD40/CD154 Pathways in Regulating Monocyte-Derived CD80 Expression During Their Interaction With Allogeneic Endothelium
    Wang, P.
    Liu, Z.
    Wu, C.
    Zhu, B.
    Wang, Y.
    Xu, H.
    TRANSPLANTATION PROCEEDINGS, 2008, 40 (08) : 2729 - 2733
  • [33] Monocyte-derived dendritic cells of patients with coronary artery disease show an increased expression of costimulatory molecules CD40, CD80 and CD86 in vitro
    Dopheide, Joern F.
    Sester, Urban
    Schlitt, Axel
    Horstick, Georg
    Rupprecht, Hans J.
    Muenzel, Thomas
    Blankenberg, Stefan
    CORONARY ARTERY DISEASE, 2007, 18 (07) : 523 - 531
  • [34] Tasmanian devil CD28 and CTLA4 capture CD80 and CD86 from adjacent cells
    Wong, Candida
    Darby, Jocelyn M.
    Murphy, Peter R.
    Pinfold, Terry L.
    Lennard, Patrick R.
    Woods, Gregory M.
    Lyons, A. Bruce
    Flies, Andrew S.
    DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY, 2021, 115
  • [35] Plasma concentrations of soluble CTLA-4, CD28, CD80 and CD86 costimulatory molecules reflect disease severity of acute asthma in children
    Ip, W. K.
    Wong, C. K.
    Leung, T. F.
    Lam, C. W. K.
    PEDIATRIC PULMONOLOGY, 2006, 41 (07) : 674 - 682
  • [36] Molecular and Functional Analyses of the Primordial Costimulatory Molecule CD80/86 and Its Receptors CD28 and CD152 (CTLA-4) in a Teleost Fish
    Lu, Tao-Zhen
    Liu, Xun
    Wu, Chang-Song
    Ma, Zi-You
    Wang, Yang
    Zhang, Yong-An
    Zhang, Xu-Jie
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [37] Expressions of CD40, CD80, and CD86 molecules by fibroblasts derived from patients with systemic sclerosis.
    Fukasawa, C
    Kawaguchi, Y
    Harigai, M
    Sugiura, T
    Takagi, K
    Ohta, S
    Hara, M
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S280 - S280
  • [38] In situ expression of the costimulatory molecules CD80 and CD86 on Langerhans cells and inflammatory dendritic epidermal cells (IDEC) in atopic dermatitis
    E. Schuller
    B. Teichmann
    J. Haberstok
    M. Moderer
    Th. Bieber
    A. Wollenberg
    Archives of Dermatological Research, 2001, 293 : 448 - 454
  • [39] Expression of the co-stimulatory molecules CD28, CD86, and CD80 on fresh human myeloma cells: A potential target for monoclonal antibody therapy.
    Yoong, Y
    Kimlinger, T
    Jelinek, DF
    Witzig, TE
    BLOOD, 2001, 98 (11) : 642A - 642A
  • [40] Expression of CD28, CTLA4, CD80, and CD86 molecules in patients with autoimmune rheumatic diseases: Implications for immunotherapy
    Sfikakis, PP
    Via, CS
    CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1997, 83 (03): : 195 - 198